Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT02872857 · ClinicalTrials.gov registry record · Phase 1

Subarachnoid Hemorrhage Recovery And Galantamine

A Phase 1 study of Subarachnoid Hemorrhage, sponsored by The University of Texas Health Science Center, Houston.

Completed
Registry status
Phase 1
Development phase
60
Enrollment target
2
Study locations

NCT02872857: Completed Phase 1 study of Subarachnoid Hemorrhage, sponsored by The University of Texas Health Science Center, Houston.

NCT02872857 is a Phase 1 study of Subarachnoid Hemorrhage that has completed, run by The University of Texas Health Science Center, Houston. The registered enrollment target is 60 participants, below the 3,585-participant average among 21 other Subarachnoid Hemorrhage trials with a reported enrollment target (98% lower). The trial reports 2 study locations across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT02872857, a Phase 1 study of Subarachnoid Hemorrhage, has completed, sponsored by The University of Texas Health Science Center, Houston.

COMPLETED
Registry status
Phase 1
Development phase
60 participants
Enrollment target
2
Study locations

Study Summary

The purpose of this study is to examine the effects of the study drug--Galantamine-on patients with subarachnoid hemorrhage (SAH). The study will examine how patients with SAH will tolerate the study drug and how it may improve brain functioning in patients after SAH.

Conditions Studied

Interventions

  • DRUG Placebo
  • DRUG 8mg galantamine twice daily
  • DRUG 12mg galantamine twice daily

Study Locations (2)

Texas

  • Houston Methodist Hospital Texas Medical Center - Houston
  • The University of Texas Health Science Center at Houston - Houston

Trial Details

FieldValue
Enrollment Target 60 participants
Start Date 2016-09
Est. Completion 2019-07-20
Phase Phase 1

What the finished NCT02872857 record still lists

NCT02872857 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 60 participants, a relatively small participant target, below the 3,585-participant average among 21 other Subarachnoid Hemorrhage trials with a reported enrollment target (98% lower).

The record links to 1 condition, with Subarachnoid Hemorrhage appearing as the primary indexed condition, and to 3 interventions - of which Placebo is the first listed.

NCT02872857 reports a single indexed study location in Texas.

Frequently Asked Questions

What is clinical trial NCT02872857 about?

NCT02872857 is a clinical study titled "Subarachnoid Hemorrhage Recovery And Galantamine". The purpose of this study is to examine the effects of the study drug--Galantamine-on patients with subarachnoid hemorrhage (SAH). The study will examine how patients with SAH will tolerate the study drug and how it may improve brain functioning in patients after SAH.

What is the current status of trial NCT02872857?

This trial is currently completed. It is a Phase 1 study. The enrollment target is 60 participants. The study started on 2016-09. Estimated completion is 2019-07-20.

What conditions does trial NCT02872857 study?

This clinical trial studies the following conditions: Subarachnoid Hemorrhage.

What interventions are being tested in trial NCT02872857?

The interventions under investigation include: Placebo (DRUG), 8mg galantamine twice daily (DRUG), 12mg galantamine twice daily (DRUG).

Who is sponsoring clinical trial NCT02872857?

This trial is sponsored by The University of Texas Health Science Center, Houston, which has 732 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT02872857 being conducted?

This trial has 2 study locations across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Subarachnoid Hemorrhage

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT02872857's enrollment target sits among peer trials

60 13th of 21 higher than 9 of 21 other Subarachnoid Hemorrhage trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Subarachnoid Hemorrhage trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT00576069 · 60 participants

    Mechanism(s)of Airflow Limitation in Moderate-severe Persistent Asthma

  • NCT01297400 · 60 participants · Phase 2

    Phase 2 Pilot Study of the Safety and Efficacy of Topical MW-III in Thermal Burns

  • NCT01734122 · 60 participants

    Stereotactic Radiosurgery for Essential Tremor and Parkinsonian Tremor

  • NCT01804634 · 60 participants · Phase 2

    Reduced Intensity Haploidentical BMT for High Risk Solid Tumors

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT02872857, the US trial registry maintained by the National Library of Medicine. NCT02872857 (small enrollment · single site footprint · completed) retrieved and formatted by PlainTrial, see methodology.